22 8 月, 2024 – Asia Featured

ACN Newswire

Datacentre & Cloud Infrastructure Summit (DCCI) gears up to transform the Kingdom’s digital future

22 8 月, 2024

Riyadh, Saudi Arabia, Aug 22, 2024 - (ACN Newswire via SeaPRwire.com) - Having debuted in Saudi Arabia last year, Datacentre & Cloud Infrastructure Summit (DCCI) is pacing for a massive return to the country on 5 – 6 November 2024 at the luxurious JW Marriott Hotel in Riyadh. Poised to gather over 300 industry leaders, experts, and key decision-makers from across the country, the platform will delve into the latest trends, innovations, ground-breaking strategies and give a pulse of the Kingdom’s datacentre & cloud landscape.With global industries expanding their footprint in the Kingdom, cutting-edge events in Riyadh have become a regular phenomenon. In line with VISION 2030, DCCI aims to upgrade the Kingdom’s technology stance by bringing global expertise closer to its datacentre & cloud ecosystem that is pivotal for a diversified economy and paramount to its digital future.To share the latest updates concerning Saudi’s digital infrastructure especially from its datacentres & cloud landscape, DCCI is bringing none other than the top officials from the leading public & private organisations including but not limited to the Ministry of Saudi Arabia National Guard, Saudi Olympic & Paralympic Committee, Saudi Pro League, Saudi Basic Industries Corporation (SABIC), Saudi Entertainment Ventures and Saudi Payments.These officials are not just the leading voices from across sectors but also the embodiment of progress who will be seen taking insightful keynote sessions, engaging fireside chats and deep dive panel discussions on the most pressing topics.Some prominent topics from the summit include, ‘Revolutionizing Saudi Arabia's Digital Infrastructure Landscape’, ‘National Data Sovereignty and Upholding Data Privacy’, ‘A Cloud-Powered Future for a Digital Saudi Arabia’, ‘Reimagining Data Centre Cooling’, ‘Reengineering Data Architecture’, ‘Empowering Next-Generation data centres through AI-Powered Infrastructure’, ‘Sustainable and Green Data Centres for a Digital Saudi Arabia’ and others.Attendees will also get the opportunity to explore the latest datacentre and cloud solutions as the platform will feature a stellar lineup of solution providers including but not limited to Edarat, Legrand Data Center Solutions, Daikin Air Conditioning Saudi Arabia, C&D Technologies, Corning, Hasoub, Austin Hughes, Nlyte Software, Sunbird Software, SETRA, Belden, Rittal, and many more.During the course of two days, DCCI will present an unparalleled opportunity to learn the latest intel, shake hands and network with industry’s very best, have one-on-one interactions with hand-picked profiles and last but not least forge strategic partnerships for growth & development.Organiser and CEO of Tradepass, Sudhir Ranjan Jena stated his organisation’s exemplary vision behind bringing this platform to the Kingdom, “The Datacentre & Cloud Infrastructure Summit (DCCI) is an effort towards powering an era that comes entwined with progress and global collaborations. With a focus on Saudi Arabia’s booming digital infrastructure landscape, DCCI will be a cornerstone for driving the latest datacentre & cloud innovations in the country that’s intrinsic to the Kingdom’s post-oil economy.”About TradepassProviding access to the global emerging markets, Tradepass brings together people, products and solutions to power events for unparalleled business and networking opportunities. Being the most accredited event company, it helps organizations: enter new markets, grow sales pipeline, close prospects, raise capital and identify the right solution-providers.As a deal facilitator, Tradepass is always determined about exposing the most agile liquid growth markets, to enable all-round scalability and growth.For more information about the event, log on to:https://saudi.dccisummit.com/Media contact:Shrinkhal SharadPR & Communication Leadinfo@tradepassglobal.com+ (91) 80 6166 4401Tradepass Copyright 2024 ACN Newswire via SeaPRwire.com.

JCN Newswire

Leqembi (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain

22 8 月, 2024

TOKYO and CAMBRIDGE, Mass., Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Aβ) monoclonal antibody “Leqembi®” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain.1 Lecanemab is indicated for the treatmentof mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein Eε4 (ApoE ε4)* heterozygotes or non-carriers.1 Lecanemab becomes the first treatment for early AD (MCI and mild dementia due to AD)2 that targets an underlying cause of the disease, to be authorized in a country in Europe.1Lecanemab selectively binds to Aβ aggregate species, with preferential activity for toxic Aβ protofibrils** (as well as fibrils, which are a major component of Aβ plaques).2,3,4 It binds to these aggregate Aβ species to neutralize and clear them from the brain.2,3,4The approval was primarily based on Phase 3 data from Eisai’s global, placebo-controlled, double-blind, parallel-group, randomized Clarity AD clinical trial, in which the medicine met its primary endpoint (change from baseline in the Clinical Dementia Rating Sum of Boxes [CDR-SB]† at 18 months) and all key secondary endpoints with statistically significant results.2 Inthe indicated population in Great Britain, the most common adverse reactions were infusion-related reaction, amyloid-related imaging abnormalities with hemorrhage (small spots of bleeding) (ARIA-H)‡, fall, headache and amyloid-related imaging abnormalities with cerebral edema (build-up of fluid) (ARIA-E)‡‡.1In the United Kingdom, it is estimated that 982,000 people are living with dementia,5 and AD is the cause in 60-70% of people with dementia.6 These numbers are expected to rise, as the population ages.5,6Eisai is working collaboratively with the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the National Health Service (NHS) to make this medicine available to eligible people living with early AD as soon as possible.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. In Great Britain, Eisai and Biogen will co-promote the medicine, with Eisai distributing the product as the Marketing Authorization holder.*Apolipoprotein E is a protein involved in the metabolism of fats in humans. It is implicated in AD.**Protofibrils are thought to be the most toxic Aβ species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms. 7 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aβ plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.8†CDR-SB is a commonly used diagnostic tool, which can help to stage dementia due to AD.9 It is a global cognitive and functional scale that measures six domains of functioning, including memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care.9‡ARIA-H: amyloid-related imaging abnormalities with hemorrhage (microhemorrhages, and superficial siderosis).‡‡ARIA-E: amyloid-related imaging abnormalities with oedema (edema/effusion).More information can be found in the Summary of Product Characteristics and Patient Information leaflets which will be published on the MHRA Products website within 7 days of approval.MEDIA CONTACTSEisai Co., Ltd.Public Relations Department TEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 7974-879-419Emea-comms@eisai.netBiogen Inc.Jack Cox+ 1-781-464-3260public.affairs@biogen.comEisai Inc. (U.S.)Libby Holman1-201-753-1945Libby_Holman@eisai.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations Department TEL: +81 (0) 3-3817-5122Biogen Inc.Chuck Triano+ 1-781-464-2442IR@biogen.comAbout lecanemab (Leqembi®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).2,3Lecanemab’s approval in Great Britain was primarily based on Phase 3 data from Eisai’s global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results.1,2 Clarity AD was a Phase 3global, placebo-controlled, double-blind, parallel-group, randomized study in 1,795 patients with early AD (MCI or milddementia due to AD, with confirmedpresence of amyloid pathology), of which 1,521 were in the indicated population in the label in Great Britain (ApoE ε4heterozygotes or non-carriers).1 Of the total number of patients randomized 31% were non-carriers, 53% were heterozygotes and 16% were homozygotes.1 The treatment group was administered lecanemab 10 mg/kg bi-weekly, with participants allocated in a 1:1 ratio to receive either placebo or lecanemab for 18 months.1The primary endpoint was the global cognitive and functional scale, CDR-SB.1 In the Clarity AD clinical trial, treatment with lecanemab, in the indicated population in Great Britain (ApoE ε4 heterozygotes or non-carriers), reduced clinical decline on CDR-SB by 33% at 18 months compared to placebo.1 The mean CDR-SB score at baseline was approximately 3.2 in both groups.1 The adjusted least-squares mean change from baseline at 18 months was 1.15 with lecanemab and 1.73 with placebo(difference, −0.58; 95% confidence interval [CI], −0.81 to −0.34; P

JCN Newswire

GR Supra GT4 EVO2 Launched for 2025 Season

22 8 月, 2024

Toyota City, Japan, Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - TOYOTA GAZOO Racing (TGR) began accepting orders today for the new GR Supra GT4 EVO2, for which vast feedback from racing teams and drivers around the world was leveraged to achieve higher levels of performance, reliability, and operability.Since the launch of the GR Supra GT4 in 2020, thanks to the support of race organizers and customers, cumulative sales(1) of the model have surpassed 120 units. The efforts of racing teams and drivers have enabled it to win GT4-series races and international races in 11 countries and regions, earn more than 500 podium finishes(2), and become the class champion in three regions: Asia, the United States, and Europe.An updated GR Supra GT4 EVO for the 2023 season featured improved braking, handling, and engine performance, making the car easier to drive for drivers of various skill levels. Yet, after that update, with there being no end to its efforts to make ever-better motorsports-bred cars, TGR continued to travel to race tracks around the world to directly receive valuable feedback from racing teams and drivers that can only be obtained under the extreme conditions of racing. Advancing its "driver-first car-making" approach for leveraging such insights into development, TGR has set the race debut of the GR Supra GT4 EVO2, with improved performance, reliability, and operability, at the start of the 2025 season.Specifically, ABS maps were meticulously re-tuned through driving by various drivers on circuits in Japan and Europe to enable optimal braking and cornering based on tire type and wear and the condition of the course. Additionally, downshifting time has been reduced by fine-tuning the rev matching through a software update, leading to enhanced deceleration control during braking for increased cornering speed. Also, in addition to improving the cooling performance of the engine, brakes, and drivetrain, cockpit temperatures have been optimized to make the car easier to drive even in harsh conditions, helping to maintain a high level of performance. These improvements make the GR Supra GT4 EVO2 easier to drive not only for professional racers but also for amateur drivers ambitiously competing in GT4 races worldwide.The GR Supra GT4 EVO2 is scheduled to make its world debut in January 2025 in the first round of the IMSA Michelin Pilot Challenge, held in conjunction with the 24 Hours of Daytona.GT4 sales and customer support (spare parts sales and technical support) will be handled by TOYOTA GAZOO Racing Europe GmbH in Europe, TRD U.S.A., Inc. in North America, Toyota Customizing and Development Co., Ltd. in Japan and other countries in Asia (excluding China), and Toyota Motor (China) Investment Co., Ltd. in China.(1) Including the GR Supra GT4 EVO(2) As of the end of July 2024For more information, visit https://global.toyota/en/newsroom/toyota/41393991.html. Copyright 2024 JCN Newswire via SeaPRwire.com.

Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT)

22 8 月, 2024

SHANGHAI, Aug 22, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest”, or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the launch of an Investigator-Initiated Clinical Trial (IIT) for a personalized mRNA cancer vaccine, EVM16, under the study EVM16CX01, at the Peking University Cancer Hospital and Fudan University's Cancer Hospital. This trial is designed to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 injection as a monotherapy and in combination with PD-1 antibody for patients with advanced or recurrent solid tumors. EVM16CX01 is the first-in-human (FIH) trial for EVM16.EVM16 is a novel personalized therapeutic mRNA cancer vaccine independently developed by Everest. EVM16 contains neoantigens with high immunogenicity potential that are predicted based on the unique tumor mutations of each patient by Everest’s proprietary neoantigen prediction algorithm. The vaccine uses a lipid nanoparticle (LNP) delivery system to efficiently deliver neoantigen-encoded mRNA in vivo, activating neoantigen-specific tumor-killing T cells and inhibiting tumor growth."EVM16 is the first personalized mRNA cancer vaccine independently developed by Everest using our proprietary mRNA platform. The initiation of this clinical trial is an important milestone that demonstrates our commitment to discover and develop a new generation of mRNA immunotherapies for cancer and autoimmune diseases.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.“While establishing leadership positions in nephrology, infectious disease, and autoimmune diseases, Everest will also focus on innovative modalities such as therapeutic mRNA vaccines. We look forward to seeing personalized cancer vaccines become a new clinical treatment method to serve more patients."According to the Globocan’s data in 2022, there were 19.976 million new cancer cases globally, with 9.744 million cancer-related deaths1. In the last few decades, Immunotherapy including checkpoint inhibitors has become an important part of treating some cancer types. However, they are only effective for some patients, and there is an urgent need to develop new generations of immunotherapies, such as personalized mRNA cancer vaccines, that have demonstrated early promise in clinical development. In preclinical studies, vaccination with EVM16 stimulated a strong neoantigen-specific T cell response in different mouse models and showed significant tumor growth inhibition in the syngeneic B16F10 mouse melanoma model. Preclinical data also demonstrated that the combination of EVM16 and a PD-1 antibody has synergistic effect, which supports the clinical application of the combination of EVM16 with checkpoint inhibitors. In preclinical toxicity studies, repeated dosing with EVM16 was well tolerated and safe. Taken together, the preclinical immunogenicity, efficacy and safety studies demonstrate that EVM16 is safe and has potential to bring benefits to cancer patients.Everest has built end-to-end capabilities across its proprietary mRNA platform. Our R&D team is developing multiple mRNA-based therapeutic products, as well as next generation lipid nanoparticle (LNP) delivery systems to enhance cell-mediated immune response. Our mRNA manufacturing facility in Jiashan, Zhejiang Province in China is designed to comply with global cGMP standards and is able to produce at clinical- and commercial-scale. Everest owns full global intellectual property rights to its mRNA therapeutic programs.Reference:1.Globocan 2022: https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdfAbout EVM16EVM16 is a novel personalized mRNA cancer vaccine independently developed by Everest Medicines Limited.. EVM16 contains neoantigens with high immunogenicity potential which are predicted by Everest-proprietary algorithm and uses an LNP delivery system to efficiently deliver mRNAs that express tumor neoantigens into the human body. After vaccination with EVM16, neoantigens-encoding mRNAs are delivered into cells to produce neoantigen peptides, which activate neoantigen-specific T cell immune responses to kill tumor cells, thereby inhibiting tumor growthAbout EVM16CX01 studyThe study is a FIH, dose escalation and expansion study to evaluate the safety, tolerability, immunogenicity, and initial efficacy of EVM16 injection as a single and in combination with PD-1 antibody in subjects with advanced or recurrent solid tumors.,. The primary objectives are to evaluate the safety and tolerability of EVM16 monotherapy and EVM16 in combination with PD-1 antibody in subjects with advanced or recurrent solid tumors, and to determine the recommended phase 2 dose (RP2D) of EVM16. The secondary objectives are to evaluate the immunogenicity of EVM16, and the initial efficacy of EVM16 in combination with PD-1 antibody in subjects with advanced or recurrent solid tumors.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders.For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2024 ACN Newswire via SeaPRwire.com.

JCN Newswire

MHI Begins Joint Demonstration with Kirin Group for Automation of Inbound and Outbound Warehouse Processes, and Loading and Unloading of Trucks

22 8 月, 2024

TOKYO, Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI), together with Kirin Group companies Kirin Beverage Co., Ltd. and Kirin Group Logistics Co., Ltd., in August will begin a joint demonstration aimed at establishing elemental technologies for the automation of inbound and outbound processes at beverage warehouses, and the loading and unloading of trucks. The joint demonstration will be conducted at LogiQ X Lab, a demonstration facility located within Yokohama Hardtech Hub (YHH), MHI's co-creation space in Honmoku, Yokohama, and at Kirin Group Logistics sites. The demonstration is scheduled to conclude by March 2026.For this demonstration, as part of the "Smart Connections" solutions incorporating the ΣSynX (Sigma Syncs) technology(Note1) that MHI is currently researching and developing, MHI will utilize a new type of unmanned forklift that is currently under development equipped with ΣSynX, with the aim of establishing elemental technologies that enable flexible autonomous operation and safe human-machine coordination, including appropriate load assortment in warehouse work, altering of operational routes in response to changes in placement locations and storage conditions, and highly efficient storage methods. Through this joint demonstration, MHI aims for future automation of the entire cargo handling process, from the unloading of trucks to handling of inbound and outbound warehouses process, and loading onto trucks.MHI is steadily advancing efforts to utilize "Smart Connections" solutions incorporating the ΣSynX (Sigma Syncs) technology for automation and intelligence of normal logistics warehouse work, which up to now has been conducted safely and efficiently through the expertise, experience and skills of operators, focusing on the three areas of picking, inbound and outbound processes, and the loading and unloading of trucks. Following picking, which is the handling of cargo in warehouses, MHI will pursue development and verification to support the implementation of "Smart Connections" solutions for warehouse operations in the logistics industry. MHI and Kirin Group conducted a joint demonstration of automated picking from November 2022 to June 2023.(Note2) This demonstration verified its effectiveness at logistics sites, and an automated picking solution is scheduled to start operation at Kirin Group's Ebina Logistics Center in Kanagawa Prefecture from December 2024. This new joint demonstration being conducted by the two companies will accelerate the response to the challenges posed to the logistic industry by regulatory changes implemented in 2024.Going forward, through coordination with Kirin Group for this demonstration program, MHI will work to provide solutions for the various issues faced by the beverage industry due to regulatory changes, such as the shortage of logistics operators, the need for improvement in working conditions, and reducing truck driver working hours and wait times.(1) ΣSynX (Sigma Syncs) is MHI's standard platform for synchronizing and coordinating various types of machinery systems. It consolidates a host of digital technologies that enable optimized operation by making machinery systems intelligent. For more information, please refer to the following press release. www.mhi.com/news/23100501.html(2) For more information on the joint demonstration with Kirin Group for an automated picking solution, please refer to the following press release. www.mhi.com/news/22112101.html Overview of the Joint DemonstrationImplementation period: August 2024, through March 2026Demonstration sites: MHI's LogiQ X Lab demonstration facility at Yokohama Hardtech Hub (YHH), MHI's demonstration facility at Kobe Shipyard, and Kirin Group Logistics facilities such as Nishi-Nagoya and Amagasaki.Content for the demonstration- Determining of operational processes, including manned work, assuming the introduction of warehouse inbound and outbound process solutions- Determining of operational processes, including manned work, assuming the introduction of unmanned forklifts for loading and unloading trucks- Determining of safety concepts, rules, operating conditions, and other standards for collaborative work with manned and unmanned forkliftsTags: Sigma SynX,Smart InfrastructureAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.

JCN Newswire

Techstars Tokyo Accelerator Announces Inaugural Class of 2024

22 8 月, 2024

TOKYO, Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - Techstars Tokyo Accelerator powered by JETRO and Mitsui Fudosan is proud to announce the 12 startups selected for the Class of 2024. These promising, early-stage companies are addressing challenges in categories such as Women’s Health, Gaming, Animation, Productivity Enhancement, B2B Business Intelligence, Robotics and more.Taking place in the rapidly growing tech ecosystem of Tokyo, the three-month mentorship-driven program is bringing together founders from across the globe from countries of Finland, India, Indonesia, U.S. and Vietnam along with six Japanese companies. The 2024 class was chosen for innovative products and solutions in areas that will revolutionize how entertainment industries work, how the companies manage their data, and how people live and work better.“We are thrilled to welcome the very first class of Techstars Tokyo Accelerator program,” said Yuki Shirato, Managing Director at Techstars. “This exceptionally talented and diverse group of founders demonstrates tremendous potential and we’re eager to offer our full support leveraging our network of mentors, investors and talents locally and globally and growth-focused tools and workshops, to propel them towards success.”Demo Day is scheduled on November 12th, 2024, where founders will have an opportunity to pitch their businesses to a community of mentors and potential investors.Introducing our inaugural class for the Techstars Tokyo Accelerator!- Aman (Jakarta, Indonesia)Supercharges customized employee health benefits for micro, small and medium enterprises- Amatama (Nagoya, Japan)Optimizes hierarchical computational technology development for humanoids to completely replace labor- Assethub (California, US)Provides an easy way to create unique 3D models from pictures using AI- Digital Will Inc. (Tokyo, Japan)Democratizes gaming with our AI-enhanced platform, WORTAL, for game developers- Dondon Technologies, Inc. (New Jersey, US)Accelerates 2D anime production with AI-assisted drawing tools- InfraHive (Rajasthan, India)Develops data intelligence for finance, analytics and customer teams of enterprises- March Health (California, US)Revolutionizes women’s health (endometriosis) with an AI-first clinic in your pocket- Pioneerwork (Tokyo, Japan)Automates and expedites dropshipping for retail e-commerce- Samaria Inc. (Tokyo, Japan)Unleashes the potential of Japanese manga to the world with AI- Saner.AI (Ho Chi Minh, Vietnam)Revolutionizes knowledge management for knowledge workers, particularly people with ADHD- StoryDrops (Helsinki, Finland)Builds a platform of authenticity through creating and sharing audio messages- Undesk (Tokyo, Japan)Provides a multi-player browser to improve team communication and productivityAbout TechstarsTechstars is the most active pre-seed investor in the world having invested through its accelerators in more than 3,800 companies. Founded in 2006, Techstars believes that entrepreneurs create a better future for everyone and great ideas can come from anywhere. Now we are on a mission to invest in an unprecedented number of startups per year enabling more capital to flow to more entrepreneurs around the world. We do this by operating accelerator programs and venture capital funds, as well as by connecting startups, investors, corporations, and cities to help build thriving startup communities. www.techstars.comMedia Contact for TechstarsAmalia Lytleamalia.lytle@techstars.com Copyright 2024 JCN Newswire via SeaPRwire.com.

云顶新耀宣布自主研发的新型mRNA个性化肿瘤治疗性疫苗正式启动临床试验

22 8 月, 2024

上海, 2024年8月22日 - (亚太商讯 via SeaPRwire.com) — 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布正式启动一款个性化肿瘤疫苗EVM16的研究者发起的临床试验项目（IIT）EVM16CX01。该研究由北京大学肿瘤医院和复旦大学附属肿瘤医院发起，用于评估EVM16注射液单药及联合PD-1抗体治疗在晚期或复发实体瘤受试者的安全性、耐受性、免疫原性和初步疗效的剂量递增及扩展研究。这是EVM16开展的首次人体试验。EVM16是一款云顶新耀自主研发的新型mRNA个性化肿瘤治疗性疫苗，根据每位患者特有的肿瘤细胞突变，使用自主研发的人工智能算法，预测出具有较高免疫原性潜力的新抗原。通过脂质纳米颗粒（LNP）递送系统在体内进行高效的抗原呈递，激活新抗原特异性T细胞，进而达到杀伤肿瘤细胞和治疗癌症的目的。云顶新耀首席执行官罗永庆表示：“EVM16是云顶新耀自主研发的首款个性化mRNA肿瘤疫苗，此次临床试验项目的正式启动意味着公司基于自主知识产权的mRNA平台所开发的肿瘤疫苗产品进入人体试验阶段，有望为肿瘤治疗领域开发出新一代免疫疗法。在构建肾科、感染、自身免疫性疾病领导地位的同时，云顶新耀也快速进入肿瘤治疗性疫苗等创新性治疗领域，开拓新蓝海。我们期待早日看到个性化肿瘤疫苗成为新的临床治疗手段，服务更多患者。”Globocan 2022年统计数据显示，全球新发肿瘤人数1997.6万人，因肿瘤死亡的人数为974.4万人1。以PD-1/PD-L1抑制剂为主的免疫疗法已经成为某些肿瘤治疗非常重要的一部分，但仅对部分患者有效，肿瘤治疗领域急需在此基础上开发新一代免疫疗法。个性化mRNA肿瘤疫苗则成为极具潜力的新一代免疫疗法。在临床前研究中，EVM16在多种小鼠模型中都激发出了强烈的新抗原特异性T细胞免疫反应，在小鼠黑色素瘤B16F10模型中实现了显著的肿瘤生长抑制效果。云顶新耀自研的算法已找到多个已知和之前未报道的肿瘤抗原，并且在多个独立验证研究中的预测表现相当或优于行业领先算法，临床前数据还证明了EVM16疫苗与PD-1抗体联用后的协同抗肿瘤效果，支持个性化肿瘤疫苗与免疫检查点抑制剂在临床中的联用。在临床前安全性评估试验中，EVM16疫苗也展现了良好的安全性。这些结果综合说明，EVM16注射液安全性良好，和免疫检查点抑制剂联用有望给肿瘤患者带来更多临床获益。云顶新耀利用自主知识产权的mRNA平台开发预防及治疗性的mRNA产品，且拥有这些产品的全部知识产权及全部全球权益，并同时具备治疗性mRNA产品全产业链的开发和制造能力。自研团队基于经过临床验证的mRNA技术平台，多路径开发肿瘤及其他治疗药物。目前正在研发多个mRNA肿瘤治疗药物，包括个性化肿瘤疫苗（PCV）、肿瘤相关抗原（TAA）肿瘤疫苗、免疫调节肿瘤疫苗，自体生成CAR-T产品，并开发新一代脂质纳米粒（LNP）递送系统以增强细胞介导的免疫反应。此外，云顶新耀拥有自有商业化规模生产基地，位于浙江嘉善、符合全球良好生产规范（GMP）标准认证的生产基地于2022年12月正式投入运行并成功完成了临床批次生产，为实现mRNA技术平台的本土化研发、生产以及商业化运营奠定坚实的基础。参考文献：1. Globocan 统计数据: https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf关于EVM16EVM16是一款云顶新耀医药科技有限公司自主研发的新型mRNA个性化肿瘤疫苗。EVM16是用菌种库制备得到的线性化质粒DNA为模板，经体外转录、纯化、除菌过滤制备出mRNA原液，采用脂质纳米颗粒（LNP）技术将mRNA原液包封在由特定脂质组分组成的纳米级脂质颗粒中，加入其他辅料经无菌灌装制成。EVM16根据每位患者独有的肿瘤细胞突变，使用自主研发的人工智能算法，预测出具有较高免疫原性潜力的新抗原，采用脂质纳米颗粒（LNP）递送系统将能高效表达肿瘤新抗原的mRNA递送至人体内。受试者接种EVM16注射液后，mRNA被递送入细胞内生成新抗原肽段，诱导机体产生新抗原特异性的T细胞免疫反应，来杀伤清除表达新抗原的肿瘤细胞而达到抑制肿瘤生长和治疗癌症的目的。关于EVM16CX01研究项目此研究是一项评估EVM16注射液单药及联合PD-1抗体治疗对晚期或复发实体瘤受试者的安全性、耐受性、免疫原性和初步疗效的剂量递增及扩展研究，也是EVM16的首次人体试验。主要研究目的包括评估EVM16单药以及EVM16联合PD-1 抗体在晚期或复发性实体瘤受试者中的安全性和耐受性，确定EVM16的II期推荐剂量（RP2D）；次要目的包括评估EVM16在晚期或复发性实体瘤受试者中的免疫原性，以及评估EVM16联合PD-1 抗体在晚期或复发性实体瘤受试者中的初步有效性。关于云顶新耀云顶新耀是一家专注于创新药和疫苗研发、临床开发、制造和商业化的生物制药公司，致力于满足亚洲市场尚未满足的医疗需求。云顶新耀的管理团队在中国及全球领先制药企业从事过高质量研发、临床开发、药政事务、化学制造与控制（CMC）、业务发展和商业化运营，拥有深厚的专长和丰富的经验。云顶新耀已打造多款疾病首创或者同类最佳的药物组合，公司的治疗领域包括肾科疾病、感染性和传染性疾病、自身免疫性疾病。有关更多信息，请访问公司网站： www.everestmedicines.com前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述，乃基于本公司或管理层在做出表述时对公司业务运营情况及财务状况的现有看法、相信、和现有预期，可能会使用“将”、“预期”、“预测”、“期望”、“打算”、“计划”、“相信”、“预估”、“确信”及其他类似词语进行表述。这些前瞻性表述并非对未来业绩的保证，会受到风险、不确定性及其他因素的影响，有些乃超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展等各种因素及假设的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司及各附属公司、各位董事、管理人员、顾问及代理未曾且概不承担更新该稿件所载前瞻性表述以反映在本新闻稿发布日后最新信息、未来项目或情形的任何义务，除非法律要求。 Copyright 2024 亚太商讯 via SeaPRwire.com.

ACN Newswire

赛晶科技公布2024年度中期业绩录得总收入人民币6.56亿元同比增长43%

22 8 月, 2024

2024年度中期业绩报告摘要（截至2024年6月30日止6个月）- 总收入为人民币6.56亿元，同比增加约43%；归属母公司净利润3,358万元，同比扭亏为盈。- 配输电业务方面，报告期内集团于该分领域的销售收入达人民币3.58亿元，同比大幅增长105%。其中直流输电业务同比增长177%，柔性输电业务同比增长196%。- 研发方面，将在8月底正式发布自研碳化硅（SiC MOSFET）晶片，电阻率低至13毫欧，达到了国际领先水准。香港, 2024年8月22日 - (亚太商讯 via SeaPRwire.com) — 赛晶科技集团有限公司（「赛晶科技」或「公司」，连同其附属公司统称「集团」；股份代号：0580.HK）披露截至2024年6月30日止半年度（「报告期内」）的业绩公告。报告期内，公司总收入为人民币6.56亿元，较2023年同期增长43%；归属母公司净利润3,358万元，同比扭亏为盈。其中，国内市场收入为人民币6.17亿元，较2023年同期增长40%；国外市场收入为人民币3,871万元，较2023年同期增长94%。直流输电业务高歌猛进，输配电业务营收同比增长105% 随着直流输电专案数量与市场规模的迅猛扩张，公司依托在直流输电领域稳固的行业领导地位，2024上半年输配电业务营收达到3.58亿元，同比增长105%。其中，在特高压常规直流输电板块，公司圆满交付了服务于“金上-湖北”、“哈密-重庆”、“宁夏-湖南”等国家级特高压工程专案的关键设备订单，推动该领域营收同比增长高达177%。在柔性输电板块，公司主要交付了用于德国BorWin6海上风电柔性直流输电工程及国网四川成都供电公司66KV构网型直挂静止无功发生器（SVG）的订单，实现该领域营收同比增长196%。此外，公司自主研发的柔性直流输电用直流支撑电容器，于2024年初通过国家级新技术产品鉴定，随后在“国网四川成都供电公司66KV构网型直挂静止无功发生器”及“华能玉环2号海上风电专案220千伏送出工程”等多个专案中实现批量供货，并完成了100%的国产替代。有望在后续柔性输电专案中，带来新的业绩增长空间。总体来看，常规直流输电工程、柔性输电工程的在建及储备专案丰富。上半年“金上-湖北”等专案顺利推进，同时“陕北-安徽”等多地储备专案蓄势待发，国外专案如“沙特中西和中南”等也有望开工。此外，“疆电送电川渝”等特高压专案公布，新型输电技术如低频、远海风电直流等不断涌现，拓宽市场空间。直流输电行业快速增长，新技术需求旺盛，公司将凭借领先地位，将持续推动业绩高增长。功率半导体业务客户数量大幅增长，晶片研发成果显著上半年，公司自研功率半导体业务的市场推广和客户开拓工作依然取得了显著成绩。2024年上半年，尽管销售收入受到一定影响，但客户总数实现了同比104%、环比45%的大幅增长。其中，完成测试和供应商导入工作并进入批量供货阶段的客户数量更是同比增长100%、环比增长125%。产能方面，上半年也实现了有序提升。公司已经启动了第三条IGBT模组封装测试生产线，及第一条碳化硅模组封测生产线的厂房内部建设和设备采购工作，有望在2024年底前完成生产调试前的全部准备工作。研发方面，上半年公司自研功率半导体领域取得了显著成果。下半年将有一系列功率半导体晶片推出，进一步丰富了集团的晶片产品线，为公司在高端功率半导体市场的长远发展奠定了坚实基础：- 碳化硅（SiC MOSFET）晶片的研发，电阻率低至【13】毫欧，达到了国际领先水准，将在8月底正式发布。- 采用第七代微沟槽技术的i23系列1200V / 300A IGBT晶片，即将研发完成。同时，采用i23系列晶片的1200V/800A、900A ED封装IGBT模组也将陆续推出。- i20系列IGBT晶片产品线进一步扩展，即1200V / 200A、150A、100A，1700V / 150A、100A、75A等多款晶片研发进展顺利，即将推出。- EP封装IGBT模组，研发进展顺利，即将推出。未来展望为加快构建新型电力系统，促进新能源高质量发展，推动大规模设备更新改造，国家电网公司公布：今年全年电网投资将首次超过6000亿元，比去年新增711亿元。受益于此，特高压常规和柔性直流输电，及海上风电直流送出、构网型SVG、低频输电等柔性输电领域将继续呈现旺盛的市场需求，并有助于提升本集团的业绩表现。公司继续全力加强行销开拓，促进自研功率半导体业务回升及其他各项业务继续增长。- 完 -关于赛晶科技集团有限公司赛晶科技集团有限公司（简称“赛晶科技”），香港主机板上市，股票代码0580.HK。赛晶科技是业内技术领先并深具影响力的电力电子器件供应商和系统集成商，是具备国际领先水准的创新研发型企业，在北京、浙江嘉善、江苏无锡、湖北武汉，以及欧洲的瑞士和德国，拥有十余家子公司。赛晶科技，是港股稀缺的涉及特高压输电、功率半导体、电动汽车、新能源电力行业的上市公司。赛晶科技业务涵盖生产、传输、使用的新能源全产业链，涉及光伏、风电、直流输电、智能电网、电动汽车、轨道交通、电气化船舶、储能及各类工业控制领域。特别是在特高压输电领域，赛晶科技的多款产品长期保持业内技术和市场的领先地位，已经累计参与超过40个特高压、高压输电专案。赛晶科技拥有世界一流的功率半导体研发团队，自研IGBT和SiC晶片及模组获得了电动汽车、新能源发电、储能和工业电控等领域客户的广泛认可。2023年，国内特高压输电专案密集开工，且未来多年的国内、国外市场需求潜力巨大。赛晶科技在特高压领域的行业领先地位稳固、在手订单充足、业务增长确定性极高。此外，2023年赛晶科技功率半导体业务的新产品频出、产能释放加速、市场开拓成果显著，展现出光明而广阔的发展前景。投资者及媒体查询赛晶科技集团有限公司联络人︰吉庆电话：86-10-56301205 / 86-186-11693787电邮：jq@sunking-tech.com Copyright 2024 亚太商讯 via SeaPRwire.com.

民主党周三阵容锁定关键投票群体：白人男性

22 8 月, 2024

(SeaPRwire) - 本文是 TIME 政治通讯“华盛顿简报”的一部分。订阅该通讯，以获取此类文章。对于两党最顶尖的策略家来说，每四年都会有一个数字占据他们的脑海：270。当然，这是赢得白宫所需的选举人票数基线，而卡玛拉·哈里斯或唐纳德·特朗普能够采取的路径也只有这么多。但对于一些量化分析师来说，还有一个数字讲述了乔·拜登在 2020 年击败特朗普的故事：100 万。这是拜登在六个关键战场州比希拉里·克林顿四年前的表现多出的白人男性选票数。TIME 的一项分析表明，拜登之所以能够将这些州从特朗普手中夺走，很大程度上是因为他缩小了克林顿在白人男性中失利的幅度。而拜登的团队，尽管其规模庞大，但在 2020 年还是清醒地认识到，这里一点那里一点的努力可能就是决定胜负的关键。拜登在佐治亚州的白人男性中领先克林顿 11 个百分点。亚利桑那州和密歇根州的差距缩小了 10 个百分点。威斯康星州和内华达州的差距缩小了 6 个百分点。宾夕法尼亚州缩小了 5 个百分点。北卡罗来纳州的努力是唯一失败的，但其结果仍然比 2016 年的水平提高了 3 个百分点。哈里斯的竞选团队知道他们不会赢得整体的白人男性选票，因为对手是特朗普。但他们也认为，保持与克林顿时期相当的支持率是一个优先事项。需要证据吗？看看星期三晚上的民主党全国代表大会阵容。在两位前总统奥巴马夫妇和希拉里·克林顿等重量级人物接连亮相两天后，星期三的重头戏包括哈里斯的竞选搭档蒂姆·沃兹、前总统比尔·克林顿和交通部长皮特·布蒂吉格——这三位都有可能成为任何对民主党心存疑虑的白人男性选票的“安全保障”，因为他们更频繁地出现在民主党全国代表大会上，比上个月共和党全国代表大会上的女性和有色人种候选人更突出。在现在普遍被认为是最大奖项的七个州，白人男性占选民的约三分之一。但重要的是要注意：克林顿只赢得了其中约 30% 的选票，而拜登赢得了 37% 的选票。事实上，拜登的联盟中有 26% 是白人男性，比克林顿高出 3 个百分点。是的，民主党实际上变得更白了，也变得更男性化了。在拜登表现不佳的辩论之后，他的辩护者在低声细语中不断强调拜登对这些白人男性的吸引力。他们认为，哈里斯（这位明显接班人恰好是黑人和亚裔美国人）可能无法在这些人中取得如此大的成功，甚至可能比克林顿的表现还差。民主党建制派对此并不信服，并积极表示，哈里斯将能够在那些拜登表现较弱的关键摇摆州中提高多个关键群体的支持率。他们继续对拜登施加压力，拜登尽管仍然不愿承认，但他也不得不承认批评者的看法。 [video id=VscqlNul autostart="viewable"] 在哈里斯担任总统候选人的情况下，民主党人正确地认识到，他们保住白宫的路径已经超越了威斯康星州、密歇根州和宾夕法尼亚州等所谓的“蓝墙”州。坦率地说：“蓝墙”由白人男性掌控。但哈里斯的民调显示，通往 270 张选举人票的路径可以延伸到内华达州、亚利桑那州和佐治亚州等阳光地带州。更令人兴奋的是，他们甚至可能重现 2020 年的选举地图，并将北卡罗来纳州首次涂成蓝色，这是自 2008 年以来的第一次。尽管仍然是一个很小的可能性，但民主党捐助者突然认为，这可能是一个有趣的策略，迫使唐纳德·特朗普将资金花在自己的“后院”，因为参议院的竞选已经成为一个隐秘的——而且罕见的——赢取机会。虽然白人男性在数量上占主导地位，但民主党也负担不起忽视其忠实的支柱，包括黑人选民、郊区女性和大学毕业生。但是，看看民主党本周在芝加哥举行的全国代表大会的节目安排，特别是星期三晚上，就会发现，没有人急于将“蓝墙”路线束之高阁。实际上，民主党全国代表大会的舞台安排表明，民主党人仍然认为，北方通道是阻止特朗普重返权力最简单的途径。但要实现这一目标，民主党人必须说服拜登式的联盟保持团结，并且——没有人愿意说出口的是——这意味着要让这个国家第二大投票群体克服对第一个担任主要政党提名人的有色人种女性的潜在怀疑。因此，星期三的阵容中充满了在讲台上发表演讲的白人男性。了解华盛顿最重大的问题。。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

新鸿基公司公布2024中期业绩

22 8 月, 2024

EQS 新闻 via SEAPRWire.com / 2024-08-22 / 12:00 UTC+8 审慎策略持续实现亏转盈新鸿基有限公司（香港股份代号：86）（「新鸿基公司」或「公司」，连同其附属公司「集团」）公布截至2024年6月30日止之中期业绩大幅转亏为盈，反映了集团多元化业务模式的优势，及公司在波动和不稳定的营商环境中，其战略转型所取得的进展。财务摘要截至下列日期止六个月截至下列日期止年度（百万港元） 2024年 6月 2023年 6月变动 2023年 12月收入 1,915.8 1,968.3 -2.7% 3,916.6 除税前溢利╱（亏损） 307.4 36.5 742.2% 76.6 本公司股东应占溢利╱（亏损） 75.4 (287.5) N/A (471.4) 每股基本盈利╱（亏损）（港仙） 3.9 (14.7) N/A (24.1) 中期股息（港仙） 12.0 12.0 - 14.0^ 每股账面值（港元） 10.7 11.0 -2.7% 10.8 ^ 第二次中期股息尽管市场环境充满挑战，集团2024年上半年仍录得收入1,915.8百万港元(2023年上半年：1,968.3百万港元)，主要包括来自信贷业务的利息收入1,650.2百万港元。公司股东应占溢利为75.4百万港元，而去年同期的亏损为287.5百万港元，实现显著转亏为盈。集团保持审慎态度，并积极管理其投资组合，继续维持稳健的资产负债表和充足的流动性，以把握市场失序带来的机遇。董事会宣布派发截至2024年6月30日止六个月之中期股息每股12港仙，维持与2023年上半年相同水平。业务回顾截至下例日期止六个月的除税前贡献于下例日期的分项资产（百万港元） 2024 年 6月 2023 年 6月^ 变动 2024 年 6月 2023 年 12月^ 信贷业务消费金融 400.3 553.8 -27.7% 17,598.0 18,062.9 按揭贷款 25.0 71.6 -65.1% 2,311.3 2,674.6 私募融资 -- (10.2) 不适用 -- -- 小计 425.3 615.2 -30.9% 19,909.3 20,737.5 投资管理 (358.4) (861.4) -58.4% 15,528.3 16,257.4 基金管理 1.3 16.3 -92.0% 21.6 24.9 集团管理及支援 239.2 266.4 -10.2% 4,046.5 3,849.7 总计 307.4 36.5 742.2% 39,505.7 40,869.5 ^ 经重列，因为私募融资中之定期贷款被重组至投资管理项下的特别机会信贷业务维持稳健表现，于期内贡献除税前溢利425.3百万港元，经营成本亦较去年同期减少，反映新鸿基公司一直致力提高营运效率。尽管融资环境充满挑战，基金管理业务仍保持盈利趋势。撇除2023年上半年出售East Point收入分成权的一次性影响，基金管理业务的除税前贡献与去年同期比较增长116.7%，助力集团转型为领先的另类投资平台。集团旗下基金及基金合作伙伴的总资产管理规模（「AUM」）录得强劲增长，达到12亿美元，创下该平台自2021年推出以来的最高纪录。资产管理规模的增长受益于超过130百万美元的净现金流入和约100百万美元的市场收益，几乎所有策略均有良好贡献。集团对该业务发展充满信心，尤其是在与GAM Investments的战略联盟于2024年8月1日生效后，这联盟扩展了集团的产品类别，并提升在大中华地区的客户覆盖范围和服务能力。集团的多家族办公室平台「家族办公室解决方案」持续取得进展，凭借其获得全球私募投资机会的优势，不断扩大客户群。该业务为具有相似投资方式和期限的家族办公室和高净值人士提供定制的另类投资解决方案，在与客户利益一致的基础上创造回报。投资管理部门亦录得显著改善，过去两年投资管理的整体回报率继续提高，期内获得0.4%的正收益。投资管理在内部分配资本成本348.7百万港元后，除税前亏损大幅收窄58.4%至358.4百万港元，比对2023年上半年亏损861.4百万港元。这改善主要归功于私募股权、对冲基金和企业持股的表现。特别机会和房地产则继续带来稳健回报。另类投资及房地产录得172.2百万港元未兑现收益，主要由于集团的对冲基金投资组合在积极调整至较保守的投资组合后，录得强劲回报。集团执行主席李成煌先生表示：「2024 年上半年我们一直保持审慎策略，并继续回购公司的票据。虽然减息预期带来了一些纾缓的作用，但 2024 年仍将会是复杂的一年。在全球经济复苏仍不明朗，地缘政治紧张持续，美国总统大选带来不确定性的背景下，我们对市场前景保持审慎乐观，同时继续减少市场风险敞口。我们亦对与 GAM Investments的新联盟所带来的潜在机遇感到兴奋，并将继续加强我们的投资及分销能力。」如欲了解更多2024年中期业绩的详细资料, 请参阅业绩公告。 - 完 - 关于新鸿基有限公司新鸿基有限公司(香港股份代号:86) (「新鸿基公司」/「本公司」，连同其附属公司「本集团」) 是一家领先的香港金融机构，在另类投资和财富管理领域备受肯定。新鸿基公司成立于1969年，其多元化的投资组合，涵盖公开市场、信贷和另类投资策略(其中包括房地产和私募股权)，缔造长期经风险调整回报。凭借其扎根亚洲的传承，新鸿基公司支持和培育该地区优秀且具专业能力的新晋资产管理公司，赋能他们实现卓越表现。集团亦利用其长久以来建立的投资业务专长和丰富资源，透过其家族办公室解决方案，为理念一致的合作伙伴和超高净值投资者提供量身定制的投资解决方案。截至2024年6月30日，集团的资产总值约为395亿港元。如欲了解更多关于新鸿基公司的资讯，请浏览：www.shkco.com / 或在 LinkedIn 上关注我们。媒体查询，请联络： Hill and Knowlton 林贵珍 +852 9839 6552 冷书杰 +852 5443 4320 张梦莹 +852 9794 5751 电邮：SHKCo@hkstrategies.com 2024-08-22 此财经新闻稿由EQS Group via SEAPRWire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php

ACN Newswire

DreamFolks Expands Footprint to SEAsian Market

22 8 月, 2024

SINGAPORE, Aug 20, 2024 - (ACN Newswire via SeaPRwire.com) - DreamFolks, India's largest airport services aggregator, is proud to announce its strategic expansion into the Southeast Asian market. This milestone marks a significant step in DreamFolks' mission to redefine travel experiences on a global scale.Over the past 12 years, DreamFolks has revolutionized the airport services industry in India by offering a comprehensive suite of premium services through its proprietary technology platform. The company dominates the Indian domestic lounge access market for debit and credit card programs, boasting an impressive 90% market share and partnerships with most major banks and card networks in the country. The Company went public in September’22 with listings on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).DreamFolks' success stems from its cutting-edge in-house technology, which empowers banks and card networks to significantly enhance their card value propositions. This technology helps boost sales, drives loyalty and optimizes cost for these financial institutions. This tech-driven approach has been key to DreamFolks' success in India and will continue to fuel its expansion into other geographies.The company's global footprint now extends to over 3000 touchpoints across more than 100 countries and 500+ cities, serving millions of travellers annually. This extensive network positions DreamFolks uniquely to offer unparalleled service to its clients and their customers in the new markets.Building on its success in the Indian market, DreamFolks is now poised to bring its innovative service aggregation model to the Southeast Asian market with services like airport and railway lounges, e-SIM: travel SIM cards, meet and assist services, airport transfers, golf privileges and more to their customers.As part of this expansion, DreamFolks has established a regional office in Singapore, demonstrating its commitment to the market. The company has also bolstered its leadership team by on-boarding, Adib Kangda, Senior Vice President – International Markets, a seasoned professional with extensive knowledge of the local market dynamics.Liberatha Kallat, Chairperson and Managing Director of DreamFolks, commented on the expansion and said, "Our expansion into Southeast Asia marks a significant milestone in DreamFolks' journey. We're not just entering new markets; we're bringing our vision of seamless, technology-driven travel experiences to one of the world's most dynamic regions. This area represents immense opportunities for growth and innovation in the travel sector. With our proven track record in India, we're confident that our unique service aggregation model will resonate strongly with banks, card networks and enterprises across the region. By entering the Southeast Asian market, we will introduce market-first card innovations, and significantly save costs for our clients. Our focus is on delivering tangible benefits for our clients, ensuring they experience enhanced value and efficiency."This expansion is expected to benefit both clients and travellers in the region. By offering its advanced technology solutions, DreamFolks aims to help banks, card networks and enterprises optimise their offerings, enhance customer loyalty, and streamline operations. For travellers, this means access to a broader range of premium services and a more seamless travel experience. This expansion not only marks a new chapter in DreamFolks' journey but also promises to elevate the standards of travel services across the region.About DreamFolksDreamFolks is a leading travel & lifestyle services aggregator and provides an in-house technology platform that allows its clients such as Banks, Card Networks, Airlines, OTAs, and Enterprises to create custom offerings for their end consumers. DreamFolks today manages the lounge and other benefits for most of the top Banks in India and enjoys a market share of over 90% in the domestic lounge access market for India-issued debit and credit programs. The company went public in Sep ’22 with listings on both BSE and NSE and has a global footprint extending to 3,000+ touchpoints in 100+ countries, across the world.For more information, please visit our website (www.dreamfolks.com) or contact our media relations team.Contact Information: dreamfolks@adfactorspr.comNamrata Sharma – Namrata.sharma@adfactorspr.com Copyright 2024 ACN Newswire via SeaPRwire.com.

泰勒·斯威夫特凭借欧洲巡演最终场打破重大纪录

21 8 月, 2024

(SeaPRwire) - 泰勒·斯威夫特成为首位在伦敦温布利体育场单场巡演中演出八次的独唱艺术家，打破了此前由迈克尔·杰克逊保持的记录，后者在 1988 年曾在伦敦这个标志性的体育场演出七次。 “你们刚刚让我成为首位在温布利单场巡演中演出八次的独唱艺术家，”斯威夫特在 8 月 20 日她在英国这个标志性场地的 2024 年最后一场演出中说道。“我们永远无法感谢你们的支持。” 这位 34 岁的歌手在 6 月份在温布利演出三场，然后在 8 月份回到该场地又演出五场，标志着“时代巡演”欧洲站的结束。自斯威夫特的巡演于 2023 年 3 月开始以来，已经打破了其他一些记录。今年 6 月初，苏格兰爱丁堡的歌迷们在斯威夫特的演出中。同月，她在温布利体育场的演出也打破了单场音乐会移动数据使用量最多的记录。据报道，使用了 5.57 TB 的数据，相当于连续十年不间断地听斯威夫特的所有音乐作品，据报道。但这项巡演并非没有遇到困难。8 月初，维也纳的恐怖袭击阴谋被挫败，导致奥地利首都的全部三场演出被取消。一些也被取消。然而，警方确认演出将继续进行。“目前没有证据表明奥地利当局正在调查的事项会对伦敦即将举行的活动产生影响，”伦敦大都会警察局发言人本月早些时候告诉 TIME。“大都会警察局与场馆安全团队和其他合作伙伴紧密合作，确保有适当的安全和警务计划到位。” 斯威夫特在温布利体育场的最后一场“时代巡演”包括她的长期制作人和合作者杰克·安东诺夫的演出，以及埃德·希兰和弗洛伦斯·威尔奇，两人都曾与斯威夫特合唱过歌曲。斯威夫特还为歌迷献上了她最近专辑中歌曲“So Long, London”的惊喜演出，。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Finance

加州医疗服务提供商扩展 Knightscope 机器人合同

21 8 月, 2024

(SeaPRwire) - MOUNTAIN VIEW, Calif., 2024年8月21日–. [Nasdaq:KSCP] (“Knightscope” 或“公司”)，一家专注于公共安全的机器人和人工智能 (“AI”) 技术创新公司，今天宣布，其位于加州的一家长期医疗保健客户已经扩展了其合同，订阅了另一个 (“ASR”)。该客户最初在 2023 年部署了其第一台 K5 ASR，并根据该成功经验，决定为第二个地点增加一台机器人。美国各地的医疗保健机构多年来一直与 Knightscope 合作，在紧急通信、人身安全和提高患者满意度等多个关键领域取得进步。这些技术的采用甚至可能帮助医疗保健机构维持或提高其 HCAHPS 评分，该评分是首个针对患者对医院护理意见的全国性、标准化、公开报告的调查。第五代 K5 ASR 由专有的 AI 软件驱动，可在加强财产安全措施的同时，为访客提供独特的交互式宾客体验，包括银行专用图形、客户选择的自定义音频广播消息语音、改善对紧急服务的访问以及大量机器人自拍机会。 K5 是公司的全自动（即无需人工干预即可操作）户外机器人，能够全天候 365 天不间断地监视财产。机器人庞大的体积以及醒目的灯光、警示灯、广播消息和巡逻声音可以有效地阻止非法活动，而其传感器收集的证据质量视频和公开数据可以帮助调查。获取专家帮助立即预约发现电话或演示，了解 Knightscope 的公共安全技术组合，包括公司的团队提供的监控的自动安全机器人。关于 Knightscope Knightscope 构建尖端技术来提高公共安全，我们的长期目标是使美利坚合众国成为世界上最安全的国家。了解有关我们的更多信息，请访问。前瞻性声明本新闻稿包含 1995 年《私人证券诉讼改革法案》含义内的“前瞻性声明”。此类前瞻性声明可以通过使用诸如“应”、“可能”、“打算”、“预期”、“相信”、“估计”、“预测”、“预测”、“预计”、“计划”、“提议”等词语来识别，以及类似的表达。本新闻稿及其他通讯中包含的前瞻性声明包括但不限于有关公司目标、盈利能力、增长、前景、费用减少和前景的声明。尽管 Knightscope 相信这些前瞻性声明中反映的预期是基于合理假设，但仍存在一些风险、不确定因素和其他重要因素可能导致实际结果与这些前瞻性声明存在重大差异，包括 Knightscope 在截至 2023 年 12 月 31 日的年度报告 10-K 表格的“风险因素”标题下讨论的因素，并由其向美国证券交易委员会提交的其他文件更新。前瞻性声明仅代表其所载文件的日期，Knightscope 不承担任何义务更新任何前瞻性声明，除非法律可能要求。联系方式公共关系： Stacy Stephens Knightscope, Inc. (650) 924-1025 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

“希望正在卷土重来”：米歇尔·奥巴马在2024年民主党全国代表大会上的关键时刻

21 8 月, 2024

(SeaPRwire) - 前第一夫人米歇尔·奥巴马周二晚上重返政治舞台，回到她的家乡芝加哥，为民主党全国代表大会上的副总统卡玛拉·哈里斯拉票。她受到了大会人群的热烈掌声，提醒着美国人为什么她仍然是该党最有影响力的人物之一——即使是在幕后。奥巴马回忆了她与哈里斯长达20多年的友谊，并谈到了对未来的共同乐观情绪，以及对该党在11月大选之前面临挑战的冷静现实。 “我们的命运掌握在我们手中，”奥巴马说。“在77天内，我们有能力让我们的国家摆脱过去的恐惧、分裂和狭隘。我们有能力将希望与行动结合起来。” 奥巴马在民主党立法者和代表们面前的演讲尤其令人感慨，因为她在本选举周期中一直保持低调，并一直避免参与党派政治的激烈争斗，而是选择通过她的倡议和公开演讲来关注更广泛的社会问题。但奥巴马和她的丈夫前总统巴拉克·奥巴马仍然在民主党人中广受欢迎——这也是她被认为是拜登总统退出竞选后接任总统候选人的人选之一的原因。奥巴马夫妇在拜登退出竞选后迅速支持哈里斯，称她具备应对当下挑战的性格和经验。 “她是史上最合格的总统候选人之一，”奥巴马周二晚上说。“她也是最尊贵的人之一——向她母亲、我的母亲，以及可能也是你的母亲致敬。她是我们对自己国家讲述的故事的化身。她的故事就是你的故事。是我的故事。是大多数美国人试图创造更美好生活的故事。” 以下是米歇尔·奥巴马在民主党全国代表大会上的演讲中的一些重要时刻。 ‘希望正在回归’ 前第一夫人重申了在她丈夫早期竞选活动中成为口号的希望信息，赞扬了哈里斯竞选活动中重新燃起的活力。奥巴马在演讲开始时提到了“希望的传染力”，告诉大会人群，“空气中有一种奇妙的魔力，不是吗？” “你知道我在说什么吗？这是希望的传染力！”她说。“再次站在光明未来的边缘时的兴奋……美国，希望正在回归。” ‘做点什么’ 但奥巴马告诫说，乐观不应该导致自满，她敦促听众在未来几周采取直接行动，帮助哈里斯取得胜利并击败前总统唐纳德·特朗普。 “当我们拥抱这种重燃的希望时，让我们不要忘记我们所感受到的绝望，”她说，提醒民主党人这次选举的利害关系，并补充说他们面临着“艰苦的战斗”。 “这取决于我们去记住卡玛拉的母亲对她说过的话：‘不要只是坐在那里抱怨。做点什么，”奥巴马补充说，这时大会人群高呼：“做点什么！做点什么！” ‘卡玛拉·哈里斯已做好准备’ 奥巴马称哈里斯为“史上最合格的总统候选人之一”，并特别关注她的背景——由一位来自中产阶级的移民母亲抚养长大，就读于一所历史性的黑人大学，并一路努力成为副总统。 “卡玛拉·哈里斯已做好准备，”奥巴马说。“卡玛拉知道，就像我们知道的那样，无论你来自哪里，你是什么样的人，你爱谁，你如何崇拜，或者你的银行账户里有多少钱，我们都应该有机会创造体面的生活。我们所有的贡献都应该得到认可和重视。因为没有人能垄断成为美国人的意义。” 总统职位‘可能只是一份黑人工作’ 奥巴马在演讲的一部分中谈到了针对哈里斯的种族主义言论和攻击性言论，警告说人们“会尽一切努力歪曲”她的背景和成就。“我和我丈夫，不幸的是，对此略知一二，”她说，然后点名批评特朗普，他散布了针对巴拉克·奥巴马毫无根据的“出生证明”谣言。 “多年来，唐纳德·特朗普尽其所能试图让人们害怕我们。你看，他狭隘的世界观让他对两个勤劳、受过良好教育、成功的黑人存在感到威胁，”她说。在提到特朗普在6月辩论中发表的言论——他声称进入美国的移民正在“抢走黑人的工作”——奥巴马补充说：“谁会告诉他，他现在正在谋求的工作可能只是一份‘黑人工作’？” “这还是他那套老把戏：用丑陋的、厌女的、种族主义的谎言来代替真正的想法和解决方案，这些想法和解决方案实际上能改善人们的生活，”她说。 ‘我的内心驱使我来到这里’ 奥巴马说，她上次回到家乡芝加哥是在今年早些时候她的母亲去世的时候，她决定在民主党全国代表大会上发表演讲，以纪念她的母亲的遗产和她所做出的牺牲。她还将她的成长经历与哈里斯的成长经历进行了对比：“她很乐意做那些无名无利的、平凡的工作，这些工作世代以来一直巩固着这个国家的根基，”奥巴马说，并补充说“卡玛拉·哈里斯和我的人生都是基于这些相同的价值观。” “我甚至不知道我今晚是否能够稳稳地站在你们面前，”奥巴马说。“但我的内心驱使我来到这里，因为我有一种责任感，我要纪念她，并提醒我们所有人不要浪费我们长辈为我们创造更美好未来所做出的牺牲。”本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Finance

小鹏汽车因竞争加剧，收入预期黯淡

21 8 月, 2024

财务预测 (SeaPRwire) - 小鹏汽车 (NYSE:XPEV) 预计第三季度的收入将低于预期，预计数字将低于该公司的预期。该公司报告称，其第三季度收入预计将在 91 亿元至 98 亿元之间，而分析师预计约为 104 亿元。季度表现在 6 月份的季度业绩中，小鹏汽车的收入为 81.1 亿元人民币 (11.4 亿美元)，低于预期的 81.7 亿元人民币。尽管毛利率略微上升至 14%，增长了 1.1 个百分点，但小鹏汽车仍在与激烈的竞争和其现有电动汽车 (EV) 产品线需求下降作斗争。车辆交付小鹏汽车的目标是在第三季度交付 41,000 至 45,000 辆汽车，超过去年同期交付的 40,008 辆。该公司报告称，4 月至 6 月期间的汽车利润率提高至 6.4%，高于上一季度的 5.5%。未来计划和挑战为了增强其市场地位，小鹏汽车计划在未来三年内以 10 万元至 40 万元 (14,001.88 美元至 56,007.51 美元) 的价格更新其车型阵容，推出新款电动汽车。即将推出的 MONA M03 中型轿车将与比亚迪的 Seagull 和 Dolphin 车型以及特斯拉的 Model 3 竞争。然而，小鹏汽车的扩张计划面临挑战，特别是由于欧盟委员会对中国制造的电动汽车征收关税。该公司正在考虑在欧洲建立一家制造工厂，以减轻这些关税的影响。竞争格局小鹏汽车正在与国内玩家如比亚迪和蔚来 (NYSE:NIO) 以及包括特斯拉 (NASDAQ:TSLA) 在内的全球竞争对手展开激烈竞争。这种竞争压力加上监管障碍正在影响小鹏汽车的财务前景和市场策略。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Finance

亚马逊股票：人工智能成本上升的影响

21 8 月, 2024

亚马逊股票表现 (SeaPRwire) - 亚马逊股票 (NASDAQ:AMZN) 在大型科技股中面临着独特的挑战，因为它在人工智能 (AI) 计算方面的支出影响了其盈利能力和股票表现。在 8 月初发布财报后，亚马逊股票的表现落后于其他大型科技股。这家电子商务巨头将重点转向人工智能投资，标志着其此前削减成本措施的转变，导致利润大幅增长，股价大幅上涨。投资者担心，资本支出的增加将对现金流产生负面影响。从历史上看，当亚马逊公司强调提高盈利能力而不是增加投资时，亚马逊股票的表现会更好。最近重回投资模式的转变令投资者质疑，强劲的股价表现时期是否会暂停或结束。自财报发布以来，亚马逊的股价一直保持在财报发布前水平以下 3% 以上，而包括其他主要科技股在内的彭博七大奇迹指数在同一时期上涨了约 4%。投资者担忧和市场反应投资者担心支出增加会损害盈利能力，这一点至关重要，尤其是在利润率扩张是亚马逊股价在 7 月初达到顶峰之前上涨 30% 以上的关键驱动因素的情况下。Benchmark 的丹尼尔·库尔诺斯 (Daniel Kurnos) 认为，最近的事件可能会导致未来几个季度利润率进一步下降，因为在潜在不稳定的宏观经济环境中，公司将重新关注营收增长。亚马逊多元化的业务模式，包括零售、视频流媒体以及电影和电视，对其表现的影响与其他科技公司不同。虽然 AWS 云计算部门仍然强劲，但美国消费者需求疲软可能会对零售部门产生负面影响。投资者似乎在等待更多关于消费者行为的信息，这可能解释了为什么亚马逊股票的表现不如其他科技巨头。此外，投资者越来越担心亚马逊不断增长的现金储备以及其不支付股息。与其他主要科技公司不同，亚马逊不支付股息，在回购股票方面也行动较慢。虽然其同行已经授权了大量的回购计划，但亚马逊在 2022 年批准的 100 亿美元回购计划在 6 月底之前完成不到一半，并且在上个季度没有回购任何股票。与科技同行对比分析亚马逊面临着越来越大的压力，要求其争夺投资者资金，尤其是当 Meta Platforms Inc. (NASDAQ:META)、Alphabet Inc. (NASDAQ:GOOG) 和 Booking Holdings Inc. (NASDAQ:BKNG) 等公司开始在回购的同时发放股息时。摩根士丹利分析师布莱恩·诺瓦克 (Brian Nowak) 领导的团队表示，亚马逊的资本回报政策与同行相比影响较小。如果这种情况到 2025 年底没有改变，亚马逊的净现金余额可能占其总市值的 8%，使其成为按市值计算排名前 25 的标普 500 指数公司之一。持续的资本回报政策有可能提高亚马逊的现金流倍数。尽管存在这些挑战，但有迹象表明，投资者开始买入包括亚马逊股票在内的被打压的科技股，包括 Nvidia Corp. (NASDAQ:NVDA)、Microsoft Corp. (NASDAQ:MSFT) 和 Apple Inc. (NASDAQ:AAPL)。亚马逊的股价自 8 月 5 日的最新低点以来已经上涨了约 11%。亚马逊股价最近的下跌使其估值降至约 28 倍预期收益，这比大多数所谓的“七大奇迹”公司都低，只有 Alphabet 的倍数更低。亚马逊的估值也略高于纳斯达克 100 指数，该指数的预期收益倍数约为 26 倍。投资者继续将“七大奇迹”公司的下跌视为买入机会，并且倾向于恢复这种策略，直到它被证明无效为止。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。